BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
-6.19%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$10.8B
AUM Growth
+$10.8B
(-5.1%)
Cap. Flow
+$915M
Cap. Flow
% of AUM
8.45%
Top 10 Holdings %
Top 10 Hldgs %
77.46%
Holding
141
New
12
Increased
26
Reduced
9
Closed
6
Top Buys
| 1 |
Incyte
INCY
|
$509M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$199M |
| 3 |
DBVT
DBV Technologies
DBVT
|
$128M |
| 4 |
Neurogene
NGNE
|
$78.1M |
| 5 |
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
|
$60M |
Top Sells
| 1 |
ZGNX
Zogenix, Inc.
ZGNX
|
$111M |
| 2 |
Xoma
XOMA
|
$57M |
| 3 |
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
|
$29.2M |
| 4 |
ALDR
Alder Biopharmaceuticals, Inc.
ALDR
|
$12.4M |
| 5 |
DYAX
DYAX CORPORATION
DYAX
|
$6.97M |
Sector Composition
| 1 | Healthcare | 74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Incyte
INCY
$16.5B
| $2.15B | 19.85% | 19,474,969 +4,609,410 | +31% | +$509M |
|
|
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.39B | 12.84% | 36,029,746 +5,159,484 | +17% | +$199M |
|
|
ALXN
3
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $1.02B | 9.45% | 6,542,599 | – | – |
|
4
AbbVie
ABBV
$372B
| $782M | 7.23% | 14,373,538 | – | – |
|
5
Acadia Pharmaceuticals
ACAD
$4.38B
| $677M | 6.26% | 20,481,442 | – | – |
|
|
ANAC
6
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $487M | 4.5% | 4,135,412 +509,914 | +14% | +$60M |
|
7
BioMarin Pharmaceuticals
BMRN
$11.2B
| $429M | 3.97% | 4,076,353 -18,894 | -0.5% | -$1.99M |
|
|
GHDX
8
DELISTED
Genomic Health, Inc.
GHDX
| $289M | 2.67% | 13,658,328 +730 | +0% | +$15.4K |
|
|
DBVT
9
DBV Technologies
DBVT
$264M
| $194M | 1.8% | 5,462,019 +3,600,000 | +193% | +$128M |
|
10
BioCryst Pharmaceuticals
BCRX
$1.74B
| $161M | 1.49% | 14,110,179 +2,532,880 | +22% | +$28.9M |
|
|
DYAX
11
DELISTED
DYAX CORPORATION
DYAX
| $144M | 1.33% | 7,561,480 -365,150 | -5% | -$6.97M |
|
|
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $102M | 0.94% | 2,955,074 +150,000 | +5% | +$5.16M |
|
|
13
Neurogene
NGNE
$264M
| $94.9M | 0.88% | 6,747,332 +5,549,966 | +464% | +$78.1M |
|
14
Heron Therapeutics
HRTX
$207M
| $71M | 0.66% | 2,907,784 +100,000 | +4% | +$2.44M |
|
15
Cerus
CERS
$251M
| $61.5M | 0.57% | 13,553,275 | – | – |
|
|
BLCM
16
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $60.9M | 0.56% | 4,190,594 | – | – |
|
|
ONCE
17
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $52.7M | 0.49% | 1,262,382 | – | – |
|
|
NVTA
18
DELISTED
Invitae Corporation
NVTA
| $47.3M | 0.44% | 6,554,967 | – | – |
|
|
ARAV
19
DELISTED
Aravive, Inc. Common Stock
ARAV
| $37.4M | 0.35% | 3,241,783 -194,802 | -6% | -$2.25M |
|
|
IMGN
20
DELISTED
Immunogen Inc
IMGN
| $34.1M | 0.31% | 3,548,040 +1,227,616 | +53% | +$11.8M |
|
21
Neurocrine Biosciences
NBIX
$13.8B
| $29.9M | 0.28% | 750,739 +208,503 | +38% | +$8.3M |
|
22
Insmed
INSM
$28.8B
| $29.4M | 0.27% | 1,583,490 | – | – |
|
|
ACOR
23
DELISTED
Acorda Therapeutics, Inc.
ACOR
| $29.1M | 0.27% | 1,096,876 +357,960 | +48% | +$9.49M |
|
|
MDVN
24
DELISTED
MEDIVATION, INC.
MDVN
| $28M | 0.26% | +659,752 | New | +$28M |
|
25
Halozyme
HALO
$8.56B
| $25.9M | 0.24% | 1,931,057 | – | – |
|